Wall Street Initiates Coverage of Lycia Therapeutics with Buy Ratings on Extracellular Degrader Platform
Multiple analysts initiated Buy ratings on Lycia Therapeutics, pointing to its differentiated LYTAC platform and potential in the growing food allergy market.